Fast Five Quiz: Metastatic Melanoma

Adil Daud, MD


March 15, 2023

Dual immunotherapy with ipilimumab-nivolumab is a preferred first-line option for patients regardless of BRAF status and has demonstrated superior efficacy compared with monotherapy with either nivolumab or pembrolizumab. However, it is associated with a higher risk for immune-related toxicities. Considerations in selection of immunotherapy include performance status, medical history, concomitant therapies, comorbidities, and patient compliance with proactive monitoring and management of adverse events.

Systemic targeted therapy (BRAF-MEK) is also a recommended first-line treatment option for patients with BRAF-mutant melanoma. Randomized clinical trials that compare first-line systemic targeted therapy (BRAF-MEK) with immunotherapy are ongoing.

Learn more about the treatment of metastatic melanoma.

Editor's Recommendations


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.